BJ
INO icon

BlackRock Japan’s Inovio Pharmaceuticals INO Stock Holding History

BlackRock Japan’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-149
Closed -$18K – 1345
2014
Q3 		$18K Buy
+149
New +$18.6K ﹤0.01% 1173

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Japan's INO Position: Q4 2014 in Review

BlackRock Japan sold out of Inovio Pharmaceuticals (INO) in Q4 2014, closing a stake of 149 shares — an estimated $18K sold.

BlackRock Japan first reported a position in INO in Q3 2014 and held it in 1 quarter. The position peaked at $18K in Q3 2014. 94 funds tracked by Wall St. Rank hold INO as of Q4 2014.

  • BlackRock Japan reported no remaining Inovio Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • BlackRock Japan sold 149 Inovio Pharmaceuticals shares in Q4 2014, an estimated $18K.
  • BlackRock Japan first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • BlackRock Japan's Inovio Pharmaceuticals position peaked at $18K in Q3 2014.
  • 94 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2014.

Based on BlackRock Japan's 13F filing for Q4 2014, filed 9 Feb 2015.